Jeffrey G Spragens
CIK 1410620 · President and CEO · last filed 2024-07-17
Jeffrey G Spragens is a President and CEO who has filed 22 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing, for SABSW, was dated Jul 17, 2024. Across all open-market trades the lifetime net is +$130.9K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $3.4K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.4K
2
22
$130.9K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SABSW | Director | 394,989 | $0.01 | $3.4K | $0 | 4 | 2024-07-17 |
| SAB Biotherapeutics, Inc. (BCYPW) Delisted | Director | 13,000 | $1.10 | $14.3K | $130.9K | 1 | 2021-10-05 |
Recent Filings
22 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-07-17 | SABSW | Grant (A) | — | $0 | EDGAR |
| 2023-03-02 | SABSW | Other (J) | — | $0 | EDGAR |
| 2022-12-09 | SABSW | Grant (A) | +82,987 | $100.0K | EDGAR |
| 2022-05-23 | SABSW | Other (J) | +299,002 | $0 | EDGAR |
| 2021-10-05 | SAB Biotherapeutics, Inc. (BCYPW) Delisted | Buy (P) | +13,000 | $130.9K | EDGAR |
| 2013-04-25 | — | Grant (A) | — | $0 | |
| 2013-03-26 | — | Buy (P) | +400,000 | $100.0K | |
| 2012-10-29 | — | Exer (X) | +20,138 | $5.0K | |
| 2012-02-22 | — | Buy (P) | +250,000 | $100.0K | |
| 2012-02-17 | — | Grant (A) | — | $0 |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.